SkylineDx Presents Landmark Study on Merlin CP-GEP beyond SLNB prediction: Transforming Melanoma Risk Assessment

SkylineDx United States of America California United Kingdom Netherlands

Sentinel lymph node (SLN) status alone is not sufficient as node negative patients still experience relapse and melanoma-related death.Validates Merlin CP-GEP's prognostic power: Identifying tumors at high-risk for relapse that would otherwise be missed by traditional clinical and pathological evaluations.View original content:https://www.prnewswire.co.uk/news-releases/skylinedx-presents-landmark-study-on-merlin-cp-gep-beyond-slnb-prediction-transforming-melanoma-risk-assessment-302420719.html